Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612192 | 0.88 | CA1 (0.40) | ALDH1A1MEN1KMT2ANSD2HTT | |
| SCHEMBL13611591 | 0.85 | SMN1; SMN2 (0.35) | ALDH1A1KMT2ANSD2HTTNPSR1 | |
| SCHEMBL13612184 | 0.85 | ALDH1A1 (0.49) | TAAR1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL13604122 | 0.85 | LPL (0.47) | TP53GRIA4TAAR1TSHRALDH1A1 | |
| SCHEMBL8288351 | 0.84 | TP53 (0.42) | TP53GRIA4TAAR1TSHRALDH1A1 | |
| SCHEMBL13612187 | 0.82 | ALDH1A1 (0.42) | TAAR1ALDH1A1KMT2A | |
| SCHEMBL13611590 | 0.76 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL10282788 | 0.73 | LPL (0.40) | CA1CA2CA9 | |
| SCHEMBL13604132 | 0.72 | LPL (0.47) | ALDH1A1KMT2ANSD2HTTNPSR1 | |
| SCHEMBL8288313 | 0.70 | CA1 (0.42) | ALDH1A1KMT2ANSD2HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | TP53 1303/4885GRIA4 16/4885TAAR1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.